Newsletter Signup x

  • acute Lymphoblastic Leukaemia |
  • Immunotherapy projects

Combinatorial targeting of Anaplastic Lymphoma Kinase (ALK) for neuroblastoma immunotherapy

Professor Persis Amrolia, UCL Institute of Child Health, London

Stem cell transplant is used as a treatment of last resort in young patients with acute lymphoblastic leukaemia (ALL) whose disease has failed to respond to or relapsed after chemotherapy. Only half of patients undergoing ...

Read more
  • Acute Myeloid Leukaemia

The genetics of familial leukaemia

Dr Elspeth Payne, UCL Cancer Institute

A large number of genetic mutations have been identified in childhood AML, with any one child having between 5 and 20 mutations. The role played by these mutations, alone and in combination, is not fully ...

Read more
  • Ewing Sarcoma

The genetics of familial leukaemia

Dr Ariadna Mendoza, UCL Cancer Institute

When Ewing sarcoma, a tumour of the bone, spreads to other parts of the body, it is difficult to treat and usually fatal. This project builds on previous work that has identified a promising new ...

Read more
  • Neuroblastoma

The genetics of familial leukaemia

Dr David Gilham, Paterson Institute for Cancer Research

Neuroblastoma is one of the most common solid tumours to occur in children. It can be exceptionally difficult to treat and, despite intensive treatment, around one third of patients cannot currently be cured. In this ...

Read more
  • acute Lymphoblastic Leukaemia

The genetics of familial leukaemia

Dr Stefan Meyer, University of Manchester

Fanconi anaemia (FA) is a rare, inherited blood disorder that leads to bone marrow failure. Children with FA have a greatly increased risk of developing leukaemia. Dr Meyer’s research focuses on a gene called EVI1 which is ...

Read more
  • medulloblastoma

The genetics of familial leukaemia

Professor Geoff Pilkington, University of Portsmouth

Medullobastoma is the most common malignant brain tumour of childhood. Although 70 per cent of patients can be cured, the aggressive treatments leave many survivors with significant mental and physical disabilities. Professor Pilkington is developing ...

Read more
Load More